Finance

Beta
Lists
NAMS:NASDAQ
NewAmsterdam Pharma Company NV
34,83 USD
-0,97%
(-0,34) 1D
2-июл., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAMS...
Open
35,27 USD
High
36,34 USD
Low
33,87 USD
Mkt. cap
4,07 млд
Avg. vol.
1,21 млн
Volume
0,00
52-wk high
42,20 USD
52-wk low
18,79 USD
EPS
-1,77 USD
Beta
0,08
Shares outstanding
116,90 млн
No. of employees
100
Open
35,27 USD
High
36,34 USD
Low
33,87 USD
Mkt. cap
4,07 млд
Avg. vol.
1,21 млн
Volume
0,00
52-wk high
42,20 USD
52-wk low
18,79 USD
EPS
-1,77 USD
Beta
0,08
Shares outstanding
116,90 млн
No. of employees
100
News stories
From sources across the web
About NewAmsterdam Pharma Company NV
CEO-
Employees100
Founded2019
Headquarters-
Sector-
Websitenewamsterdampharma.com
Analyst ratings
Based on 9 analysts giving stock ratings to NAMS in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for NAMS in the last 3 months.
Highest
Current 34,83 USD
60,00 USD (+72,27%)
Average
49,00 USD (+40,68%)
Lowest
38,00 USD (+9,10%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leonid Timashev
RBC Capital
Buy
Maintained
51,00 USD
+46,4%
06/30/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
60,00 USD
+72,3%
05/12/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/08/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
45,00 USD
+29,2%
05/07/2026
Serge Belanger
Needham
Buy
Maintained
48,00 USD
+37,8%
05/07/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/07/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
05/07/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
52,00 USD
+49,3%
05/06/2026
Asad Haider
Goldman Sachs
Hold
Maintained
38,00 USD
+9,1%
05/07/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
45,00 USD
+29,2%
04/02/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
45,00 USD
+29,2%
04/02/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
49,00 USD
+40,7%
02/19/2026
James Condulis
Stifel Nicolaus
Buy
Maintained
50,00 USD
+43,6%
02/06/2026
Geoff Meacham
Citi
Buy
Maintained
55,00 USD
+57,9%
01/30/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
19,14 млн
348,00 миң
32,00 миң
3,04 млн
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27,52 млн
30,97 млн
38,59 млн
38,01 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,26 млн
24,52 млн
27,42 млн
23,45 млн
Operating expense
54,78 млн
55,49 млн
66,01 млн
61,46 млн
Total operating expenses
54,78 млн
55,49 млн
66,01 млн
61,46 млн
Operating income
-35,64 млн
-55,14 млн
-65,98 млн
-58,42 млн
Other non operating income
2,59 млн
-23,79 млн
-15,34 млн
5,94 млн
EBT including unusual items
-17,36 млн
-72,00 млн
-74,92 млн
-48,44 млн
EBT excluding unusual items
-17,36 млн
-72,00 млн
-74,92 млн
-48,44 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17,36 млн
-72,00 млн
-74,92 млн
-48,44 млн
Net profit margin
-90,70%
-20 691,09%
-234 134,38%
-1 593,45%
Earnings per share
-
-
-
-
Interest and investment income
7,06 млн
6,71 млн
6,47 млн
5,65 млн
Interest expense
-
-
-
-
Net interest expenses
7,06 млн
6,71 млн
6,47 млн
5,65 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-35,59 млн
-55,08 млн
-65,92 млн
-58,36 млн
Gain or loss from assets sale
-
1,00 миң
11,00 миң
12,00 миң
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer